vs
Side-by-side financial comparison of Evommune, Inc. (EVMN) and Maase Inc. (MAAS). Click either name above to swap in a different company.
Evommune, Inc. is the larger business by last-quarter revenue ($10.0M vs $9.9M, roughly 1.0× Maase Inc.). Maase Inc. produced more free cash flow last quarter ($-18.3M vs $-59.9M).
Evommune, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory and immunological diseases. Its pipeline includes novel candidates targeting unmet medical needs for conditions such as atopic dermatitis, psoriasis, and other immune-mediated disorders, primarily serving global healthcare markets.
EVMN vs MAAS — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2023
| Metric | | |
|---|---|---|
| Revenue | $10.0M | $9.9M |
| Net Profit | $-12.5M | — |
| Gross Margin | — | 78.7% |
| Operating Margin | -133.3% | -55.9% |
| Net Margin | -124.8% | — |
| Revenue YoY | — | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $-8.07 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $76.1M | $10.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-183.1M | $31.6M |
| Total Assets | $84.5M | $47.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $76.1M | — | ||
| Q4 22 | — | $10.9M |
| Q3 25 | $-183.1M | — | ||
| Q4 22 | — | $31.6M |
| Q3 25 | $84.5M | — | ||
| Q4 22 | — | $47.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-59.7M | $-18.2M |
| Free Cash FlowOCF − Capex | $-59.9M | $-18.3M |
| FCF MarginFCF / Revenue | -598.7% | -184.4% |
| Capex IntensityCapex / Revenue | 1.3% | 1.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-59.7M | — | ||
| Q4 22 | — | $-18.2M |
| Q3 25 | $-59.9M | — | ||
| Q4 22 | — | $-18.3M |
| Q3 25 | -598.7% | — | ||
| Q4 22 | — | -184.4% |
| Q3 25 | 1.3% | — | ||
| Q4 22 | — | 1.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EVMN
Segment breakdown not available.
MAAS
| Wealth management | $7.8M | 78% |
| Insurance consulting | $1.0M | 10% |
| Other | $975.0K | 10% |
| Asset management | $168.0K | 2% |
